First Gut Cell Genetic Markers Uncovered for IBD

Inherited Markers of Inflammatory Bowel DiseaseA groundbreaking investigation examining gene activity across 2.2 million individual cells has, for the first time, pinpointed the precise genes and cell types most responsible for driving inflammatory bowel disease. These discoveries highlight two prev

Inherited Markers of Inflammatory Bowel Disease

A groundbreaking investigation examining gene activity across 2.2 million individual cells has, for the first time, pinpointed the precise genes and cell types most responsible for driving inflammatory bowel disease. These discoveries highlight two previously overlooked mechanisms connected to IBD and indicate promising new avenues for therapeutic development. Somewhere within the genomes of most individuals diagnosed with Crohn’s disease or ulcerative colitis exists a collection of DNA variants. These inherited genetic differences are known to correlate strongly with elevated risk for developing inflammatory bowel disease. Although researchers have been aware of these variants for quite some time, their actual functional roles remained mysterious. Specifically, it was unclear which genes the variants activate or deactivate, in which particular cells this occurs, and exactly how these changes ultimately trigger inflammatory responses. A recently published study appearing in Nature during June 2026 has now resolved these questions for more than half of all previously identified IBD genetic risk regions, and the results proved unexpected. Dr Carl Anderson, serving as co-senior author from the Wellcome Sanger Institute, clarified during a press statement that genome-wide association studies had previously located where IBD risk resides in the genome, yet this new work reveals exactly which genes the risk variants interfere with and within which cell types these disruptions take place. Scientists from the Wellcome Sanger Institute, Open Targets, and Cambridge University Hospitals constructed an extensive resource they named IBDverse, representing the largest single-cell dataset of gut tissue assembled to date. By scrutinizing gene activity within approximately 2.2 million separate cells obtained from gut biopsies together with blood samples collected from 421 individuals including 125 patients experiencing Crohn’s disease, the research group succeeded in identifying the exact cells where genetic risk variants exert their influence while also revealing the genes most likely disrupted by these variants. For the first time, investigators identified 74 gene regulatory regions associated with inherited IBD genetic risk variants, thereby opening fresh research pathways. They additionally recognized certain unanticipated cell types along with key cellular processes that may serve as candidates for future drug interventions.

Mapping the Gut Environment

More than ninety percent of genetic variants connected to IBD, as well as to numerous other complex diseases, reside outside protein-coding sections of the genome, rendering them extremely difficult to interpret. A variant might occupy a stretch of DNA that appears to perform no obvious function yet still manages to elevate disease risk. Researchers had long suspected these variants modify the strength with which certain genes become activated or silenced, meaning their expression levels, but determining precisely which genes and in which cells this occurs had remained exceptionally difficult. Earlier methodological approaches suffered from a critical limitation because they assessed gene activity within mixed tissue samples that combined dozens of distinct cell types together. Consequently any effect restricted to a single specific cell type became obscured by overall averages. Single-cell RNA sequencing overcomes this obstacle by measuring gene activity within each cell separately, thereby generating a comprehensive atlas detailing the activities of every cell type. The Wellcome Sanger team therefore attempted to chart genetic activity of gut cells at an unprecedented scale. As Dr Tim Raine, co-senior author and consultant gastroenterologist at Cambridge University Hospitals, observed when planning commenced, single-cell sequencing projects ordinarily encompassed only tens of individuals, yet achieving sufficient statistical power to address these questions required obtaining tissue samples at a substantially greater scale. The ultimate success of the project depended upon the 421 participants who generously contributed blood and tissue samples. The question remained whether this number of samples would yield adequate quantities of each specialized cell type.

Revealing Hidden Genomic Secrets

The investigators successfully recovered more than two million gut cells from participant samples. Although this quantity appears vast, the presence of numerous distinct cell types performing unique functions within the gut, combined with individual genetic variations among participants, meant every cell held significant value. Each cell underwent individual examination to determine which genes were active at the moment of collection from inflammatory bowel disease patients. Researchers employed a supercomputer to detect recurring patterns of gene activity that could classify each cell type. Every analyzed cell received assignment to a cell type, at which point the project became particularly revealing. The team identified groups of cells performing varied tasks and delineated the diverse combinations of gene expression present within each cell type. This capability allowed direct comparison between gene activity patterns observed in the guts of IBD patients and those expected within healthy guts. Investigators searched for atypical gene expression patterns that might provide clues regarding the origins of inflammation. They examined whether a particular cell type might emerge as problematic and whether any genes appeared activated in unexpected ways. Most crucially, they investigated whether any unusual gene activity aligned with genomic regions previously suggested by inheritance studies to participate in disease development.

Identifying Genes and Cells Central to Inflammatory Bowel Disease

The initial major discovery revealed active gene regulatory sequences within 180 of 321 genetic regions previously associated with IBD by geneticists. Moreover the team did not merely detect indications of involvement but instead identified specific genes most likely responsible for the observed risk. In 104 of these genetic regions investigators had already formed hypotheses regarding potentially related genes, and the experiment confirmed these connections. The remaining 74 regions represented an especially valuable finding because until this point no one had determined which genetic regulatory sequences within those areas might connect to IBD. The researchers next examined the functions of genes controlled by these 180 regulatory regions, including where the genes showed activity and what roles they performed. The team located each regulatory region of interest within their newly created map of the IBD gut and determined whether the regions appeared more frequently within particular cell types. Results demonstrated that two cell types consistently showed enrichment for these sequences.

Insights from Immune Cell Analysis

Surprisingly one cell type that repeatedly emerged during searches does not typically receive attention in IBD research: dendritic cells. These specialized immune cells patrol the gut, detect potential threats, and orchestrate the immune system response. The inflammatory bowel disease risk variants operating within dendritic cells appear to diminish activity of genes participating in the notch signalling pathway, a molecular communication system that assists in regulating immune responses within gut tissue. Two specific genes within this pathway, MAML2 and ZMIZ1, exhibited particularly robust associations with the regulatory regions. Both genes encode proteins that activate notch signalling, and IBD risk variants appear to reduce their expression within dendritic cell subtypes. This reduction may compromise the gut immune system capacity to maintain equilibrium between attacking genuine threats and tolerating harmless food particles and bacteria. The study more than doubled the number of notch pathway genes implicated in IBD, thereby supplying numerous new therapeutic targets. An additional notable discovery concerned PSEN2, a gene primarily recognized for its role in early-onset Alzheimer’s disease. PSEN2 encodes a component of the gamma-secretase enzyme complex required for notch signalling function. The investigators found that IBD risk variants increase PSEN2 expression within gut epithelial and endothelial cells. This observation may clarify why gamma-secretase inhibitors developed for Alzheimer’s treatment consistently produced gut-related side effects during clinical trials.

Maintaining the Intestinal Barrier

The second major discovery involves epithelial cells that form the inner lining of the gut and maintain its protective barrier. Researchers determined that the cells most likely utilizing the genetic regulatory elements were colonocytes from the large intestine together with gut stem cells responsible for continuous renewal of the gut lining. This collection of regulatory elements controls genes that interfere with the Wnt signalling pathway, a set of molecular signals governing how cells grow, divide, and replace themselves. The gut lining undergoes complete turnover every few days through reliance upon stem cells located at the base of intestinal crypts to generate fresh cells continuously. A significant observation indicates that the gene MYC, a well-established regulator of cell proliferation and target of Wnt signalling, displays increased expression associated with Crohn’s disease risk within these gut stem cells. The authors propose that these regulatory elements impair the gut capacity to renew and repair its lining, thereby increasing susceptibility to subsequent inflammatory cascades. As Dr Bradley Harris, co-first author, emphasized, this finding suggests a possible new dimension of IBD risk involving not only immune dysfunction but also failure of the gut to sustain itself. Many of the newly identified effector genes regulate pathways previously underappreciated in IBD risk contexts, and these associations concentrated within specific gut cell types including dendritic cells and gut stem cells that are not commonly linked to the disease.

Implications for Drug Development and Future Research

The study carries substantial implications for pharmaceutical development. Several of the genes and cell types identified are already targeted by existing IBD medications. Vedolizumab addresses the protein produced by ITGA4 while tofacitinib targets JAK2. Independent identification of these genes through genetic mapping supplies human genetic validation for their mechanisms of action and enhances confidence in additional drug candidates emerging from similar approaches. The team also identified genes targeted by medications used in other diseases that may warrant consideration for repurposing in IBD treatment. One example is PRKCB, a kinase currently undergoing early-phase IBD clinical trials that now receives additional genetic support from this investigation. Researchers have produced a comprehensive map of gene expression within the IBD gut and connected 180 hereditary markers with specific genes now available for further study. Although combinations of gene variants produce varying risk profiles for IBD, possession of variants commonly observed in IBD patients does not guarantee development of Crohn’s disease, colitis, or related conditions. Genetic markers frequently represent segments of DNA consistently inherited alongside other DNA sequences that encode the actual factors of interest. The distinctive contribution of this study lies in finally matching which genetic markers may genuinely elevate IBD risk rather than merely correlating with it. Consequently scientists now understand which cellular processes merit investigation for insights into disease triggers. The project revealed that out of 321 genetic markers frequently observed in IBD patients, 180 can be connected to genes active within the gut. Furthermore many of those genes link to critical processes involving the immune system and intestinal lining. This work provides researchers with improved understanding of underlying cellular processes that may render individuals vulnerable to IBD development. Future investigations by Crohn’s and colitis scientists will determine whether notch signalling alterations in dendritic cells or impaired cell renewal truly contribute to IBD progression.